Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell aplasia and hypogammaglobulinemia are common toxicities p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wudhikarn, Kitsada, Palomba, M. Lia, Pennisi, Martina, Garcia-Recio, Marta, Flynn, Jessica R., Devlin, Sean M., Afuye, Aishat, Silverberg, Mari Lynne, Maloy, Molly A., Shah, Gunjan L., Scordo, Michael, Dahi, Parastoo B., Sauter, Craig S., Batlevi, Connie L., Santomasso, Bianca D., Mead, Elena, Seo, Susan K., Perales, Miguel-Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405315/
https://www.ncbi.nlm.nih.gov/pubmed/32759935
http://dx.doi.org/10.1038/s41408-020-00346-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405315/
https://www.ncbi.nlm.nih.gov/pubmed/32759935
http://dx.doi.org/10.1038/s41408-020-00346-7

Ejemplares similares